Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung
Open Access
- 1 January 1998
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 77 (2) , 260-269
- https://doi.org/10.1038/bjc.1998.42
Abstract
The differential diagnosis of mesothelioma, primary adenocarcinomas and pleural metastases frequently causes problems. We have used the comparative genomic hybridization (CGH) technique on 34 malignant mesotheliomas and 30 primary lung carcinomas (adenocarcinoma, including bronchoalveolar carcinoma and large-cell anaplastic carcinoma) to compare their copy number changes and to evaluate the use of CGH to distinguish between these two types of tumour. In mesothelioma, gains of genetic material occurred as frequently as losses, whereas gains predominated over losses in carcinoma. In mesothelioma, the most frequent changes were losses in 4q, 6q and 14q and gains in 15q and 7p, whereas gains in 8q, 1q, 7p, 5p and 6p were the most common changes in carcinoma. Amplification of KRAS2 was detected in two adenocarcinomas by Southern blot analysis. CGH showed gains in 12p in the same tumours. Statistically significant differences between the two types of tumour were detected in chromosomes X, 1, 2p, 4, 8q, 10q, 12p, 14q, 15q and 18q. When comparing the frequency of gains and losses between mesothelioma and lung carcinoma using discriminant analysis, the sensitivity of CGH to differentiate mesotheliomas from lung carcinomas was 81% and the specificity 77%. The differences in DNA copy number changes between the two types of tumour suggest that they are genetically different tumour entities. Although CGH cannot be used as a definitive discriminatory method, we were able to distinguish between mesothelioma and lung carcinoma in a large proportion of the abnormal cases.Keywords
This publication has 29 references indexed in Scilit:
- Glutathione S-Transferase and N-Acetyltransferase Genotypes and Asbestos-Associated Pulmonary DisordersJNCI Journal of the National Cancer Institute, 1996
- Calretinin: A Novel Immunocytochemical Marker for MesotheliomaThe American Journal of Surgical Pathology, 1996
- Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridizationCancer Genetics and Cytogenetics, 1996
- OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.Journal of Clinical Pathology, 1995
- Differentiation of adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproducibility of immunoreactive antibodiesHistopathology, 1994
- Cytogenetic analysis of 63 non‐small cell lung carcinomas: Recurrent chromosome alterations amid frequent and widespread genomic upheavalGenes, Chromosomes and Cancer, 1994
- Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumorsGenes, Chromosomes and Cancer, 1994
- Chromosome abnormalities in non‐small cell lung cancer pleural effusions: Cytogenetic indicators of disease subgroupsGenes, Chromosomes and Cancer, 1993
- Cytogenetics of non‐small cell lung cancer: Analysis of consistent non‐random abnormalitiesGenes, Chromosomes and Cancer, 1990
- Malignant Mesothelioma of the PleuraMayo Clinic Proceedings, 1988